The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Biogen, Stoke Therapeutics Partner For Zorevunersen To Treat Dravet Syndrome February 18, 2025 — 08:31 am EST Written by RTTNews.com for RTTNews -> ...

Andrew Fein has given his Buy rating due to a combination of factors that highlight the potential efficacy and strategic direction of Stoke Therapeutics’ treatment, zorevunersen. The data from ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

About Zorevunersen Zorevunersen is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.

(RTTNews) - Stoke Therapeutics (STOK) announced that it has received Breakthrough Therapy Designation from the FDA for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation ...

Biogen receives exclusive rights to commercialize zorevunersen in the rest of the world. Upon closing of this transaction, Stoke will receive an upfront payment of $165M.

Zorevunersen is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both ...